A key witness in a bellwether trial in the Actos multidistrict litigation says that he was not an employee required to ensure compliance with a corporate integrity agreement entered into by Eli Lilly and Co. for over-promotion of Zyprexa.
The plaintiff alleges that witness Ron Hoven, a former senior director for global marketing and a witness for defendant Eli Lilly, lied in his testimony about his involvement with Zyprexa.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
